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Abstract
Background: Deciphering the mechanisms that modulate the inflammatory response induced by microglial
activation not only improves our insight into neuroinflammation but also provides avenues for designing novel
therapies that could halt inflammation-induced neuronal degeneration. Decreasing glycogen synthase kinase-3b
(GSK-3b) activity has therapeutic benefits in inflammatory diseases. However, the exact molecular mechanisms
underlying GSK-3b inactivation-mediated suppression of the inflammatory response induced by microglial
activation have not been completely clarified. Tumor necrosis factor-a (TNF-a) plays a central role in injury caused
by neuroinflammation. We investigated the regulatory effect of GSK-3b on TNF-a production by microglia to
discern the molecular mechanisms of this modulation.
Methods: Lipopolysaccharide (LPS) was used to induce an inflammatory response in cultured primary microglia or
murine BV-2 microglial cells. Release of TNF-a was measured by ELISA. Signaling molecules were analyzed by
western blotting, and activation of NF-B and AP-1 was measured by ELISA-based DNA binding analysis and
luciferase reporter assay. Protein interaction was examined by coimmunoprecipitation.
Results: Inhibition of GSK-3b by selective GSK-3b inhibitors or by RNA interference attenuated LPS-induced TNF-a
production in cultured microglia. Exploration of the mechanisms by which GSK-3b positively regulates
inflammatory response showed that LPS-induced IB-a degradation, NF-Bp65 nuclear translocation, and p65 DNA
binding activity were not affected by inhibition of GSK-3b activity. However, GSK-3b inactivation inhibited
transactivation activity of p65 by deacetylating p65 at lysine 310. Furthermore, we also demonstrated a functional
interaction between mixed lineage kinase 3 (MLK3) and GSK-3b during LPS-induced TNF-a production in microglia.
The phosphorylated levels of MLK3, MKK4, and JNK were increased upon LPS treatment. Decreasing GSK-3b activity
blocked MLK3 signaling cascades through disruption of MLK3 dimerization-induced autophosphorylation, ultimately
leading to a decrease in TNF-a secretion.
Conclusion: These results suggest that inactivation of GSK-3b might represent a potential strategy to
downregulate microglia-mediated inflammatory processes.
Background
Inflammatory processes, involving a host of cytokines,
have been shown to be associated with ongoing neuro-
nal degeneration in several neurodegenerative diseases.
Activation of glial cells such as microglia and astrocytes
is a characteristic finding in brain inflammation. Micro-
glia, as the immunocompetent resident cells of the
brain, possess properties particularly suitable for mediat-
ing cellular inflammatory responses. The secretion of
pro-inflammatory and neurotoxic mediators from acti-
vated microglia is believed to contribute to progressive
damage in neurodegenerative disorders [1-3]. Therefore,
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caused by microglial activation and its effects on brain
are vital for understanding the pathogenesis of these
diseases.
Glycogen synthase kinase 3 (GSK-3) is a multifunc-
tional serine/threonine kinase found in all eukaryotes.
There are two highly homologous mammalian isoforms
of GSK-3, GSK-3a and GSK-3b. GSK-3b is a key regula-
tor of numerous signaling pathways, and is involved in a
wide range of cellular processes ranging from glycogen
metabolism to the regulation of cell survival and neuro-
nal polarity [4,5]. Furthermore, the function of GSK-3b
in signaling mechanisms that activate nuclear factor B
(NF-B), as well as the resulting effects on NF-B-
mediated gene expression, indicate that GSK-3b acts as
a regulator of inflammation [6-8]. Although an effect of
GSK-3b in modulation of inflammation has been identi-
fied, the potential role and mechanism for this effect are
still controversial. Inhibition of GSK-3b by pharmacolo-
gical inhibitors or by overexpression of a dominant
negative mutant of GSK-3b enhances tumor necrosis
factor-a (TNF-a) expression in lipopolysaccharide-
(LPS-)stimulated cardiomyocytes [9]. Another report has
implicated GSK-3b in inhibition of TNF-a-a n di n t e r -
leukin- (IL-)1b-induced inflammatory gene expression
[10]. Conversely, the identification of GSK-3b as a
major regulator of peripheral inflammatory responses
has shown that GSK-3b promotes the stimulus-induced
production of several cytokines and the subsequent
development of disease symptoms in animal models of
inflammatory conditions [11]. Recently, GSK-3b inacti-
vation has been shown to downregulate the inflamma-
tory response induced by microglial activation [12,13].
However, the molecular mechanisms of downstream sig-
nal transduction leading to this anti-inflammatory effect
of GSK-3b inhibition in microglia are not yet clearly
understood.
TNF-a is a pro-inflammatory cytokine that is upregu-
l a t e di nt h eb r a i ni nr e s p o n s et ov a r i o u si n s u l t so r
injury. Activated microglia around an injured area have
been shown to be the major source of this cytokine.
Within the brain, inflammatory processes might be
modulated by TNF-a through further activation of
microglia and astrocytes [14,15]. TNF-a is known to
induce generation of reactive oxygen intermediates asso-
ciated with necrotic cell death, and it also induces
changes in mitochondrial ultrastructure and function
[16,17]. In addition, TNF-a also directly induces neuro-
nal death by binding to TNF receptor 1 to trigger intra-
cellular death-related signaling pathways [18]. Increased
TNF-a production is seen in several neurodegenerative
diseases and may contribute to secondary damage that
further worsens a disease state [19-22]. For example, in
Parkinson’s disease (PD), significant increases in the
expression of TNF-a and its receptors have been
reported in the caudate and putamen of postmortem
brain samples from patients with PD [20]. Several stu-
dies have demonstrated that blocking soluble TNF sig-
naling attenuates loss of dopaminergic neurons in
cellular and animal models of PD [23,24]. Moreover,
increasing basic science, genetic, and clinical evidence
now supports the concept that excess TNF-a plays a
central role in Alzheimer’s disease (AD) [19,25-27].
Administration of a TNF-a antagonist has been shown
to improve cognition in AD patients [28], and to yield a
mild increase in survival in a mouse model of amyo-
trophic lateral sclerosis [29]. Therefore, TNF-a can be
considered to be a central mechanism of injury caused
by neuroinflammation. The present study was initiated
to evaluate the role of GSK-3b in the regulation of
TNF-a production by microglia to discern the molecular
mechanisms of this modulation.
Methods
Materials
LPS from Escherichia coli serotype O111:B4, AR-
A014418, TWS119, TDZD, L803-mts, SP600125, K252a,
BAY 11-7082 and pyrrolidinedithiocarbamate (PDTC)
were obtained from Calbiochem (San Diego, CA). Cell
culture ingredients were purchased from Invitrogen
(Carlsbad, CA). Monoclonal mouse anti-transcription fac-
tor IIB (TFIIB) antibody was purchased from BD Bios-
ciences (San Diego, CA). Polyclonal rabbit anti-phospho-
M i x e dl i n e a g ek i n a s e3( M L K 3 )w a sf r o mU p s t a t eB i o -
technology (Lake Placid, NY). Polyclonal rabbit anti-acetyl
p65 and polyclonal rabbit anti-phospho-p65 (Ser276)
were obtained from Abcam (Cambridge, UK). Antibodies
against ERKs and phospho-ERKs were from Promega
(Madison, WI). All other antibodies were from Cell Sig-
naling Technology (Beverly, MA). All other reagents were
from Sigma-Aldrich (St. Louis, MO).
Microglial cultures
Primary microglia were prepared from ventral mesence-
phalon of 1-day-old Sprague-Dawley (SD) rats as pre-
viously described [30]. Briefly, ventral mesencephalic
tissues, devoid of meninges and blood vessels, were dis-
sociated by a mild mechanical trituration. The isolated
cells (5 × 10
7) were seeded in 150-cm
2 culture flasks in
Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 μg/ml streptomycin. The cells were maintained
at 37°C in a humidified atmosphere of 5% CO2 and 95%
air. The medium were changed 4 days later. Upon
reaching confluence (12-14 days), microglia were sepa-
rated from astrocytes by shaking the flasks for 2 hr at
180 rpm. Detached cells were plated into 24-wells plate
in DMEM supplemented with 10% FBS, 100 U/ml
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2.5 × 10
5 cells per well. After 2 h of incubation at 37°C,
nonadherent cells were removed. The purity of micro-
glia cultures was assessed by using OX-42 antibody and
more than 95% of cells were stained positively. Cells
were cultured for 2 days before treatment.
Murine BV-2 microglial cells were maintained in
DMEM supplemented with 10% FBS, 100 U/ml penicil-
lin and 100 μg/ml streptomycin at 37°C in a humidified
incubator under 5% CO2. Confluent cultures were tryp-
sanized. Cells were plated into 24-wells plate at a den-
sity of 2 × 10
5 cells per well and then incubated for 24
h before treatment.
Real-time RT-PCR analysis
The level of TNF-a gene expression was quantified using
real-time RT-PCR analysis. Briefly, total RNA was
extracted from microglia cultures with a cold RNA extrac-
tion solution (Ultraspec RNA; Biotecx Lab. Inc., Houston,
TX). Total RNA was reverse transcribed with M-MLV
reverse transcriptase and oligo-dT primers (SuperScript™-
First-Strand Synthesis System, Invitrogen). The primer
sequences are as follows: for mouse TNF-a,5 ’-TTC TGT
CTA CTG AAC TTC GGG GTG ATC GGT CC-3’ and
5’-GTA TGA GAT AGC AAA TCG GCT GAC GGT
GTG GG-3’; for mouse b-actin, 5’-GTG GGC CGC TCT
AGG CAC CAA-3’ and 5’-CTC TTT GAT GTC ACG
CAC GAT TTC-3’;f o rr a tT N F - a,5 ’-CAG GGC AAT
GAT CCC AAA GTA-3’ and 5’-GCA GTC AGA TCA
TCT TCT CGA-3’;f o rr a tb-actin, 5’-TTG TAA CCA
ACT GGG ACG ATA TGG-3’ and 5’-GAT CTT GAT
CTT CAT GGT GCT AGG-3’.T h eS Y B Rg r e e nD N A
PCR kit (Applied Biosystems, Foster City, CA) was used
for real-time PCR analysis. The relative differences in
expression between groups were analyzed on the basis of
cycle time (Ct) values normalized with b-actin.
Preparation of whole cell and nuclear extracts
Cells cultured in 10-cm Petri-dishes were washed twice
with ice-cold PBS and lysed in M-PER® mammalian pro-
tein extraction reagent (Pierce, Rockford, IL) containing
5 mM sodium orthovanadate, 1 mM PMSF, 10 μg/ml
aprotinin, 10 μg/ml leupeptin, and 5 μg/ml pepstain A.
After incubation for 5 min, cell lysates were centrifuged
and the supernatants were collected. Nuclear extracts
were prepared by using the NE-PER® nuclear and cyto-
plasmic extraction reagents (Pierce) as per the manufac-
turer’s instructions. Protein concentration of samples
was determined by Bradford assay (Bio-Rad, Hemel,
Hempstead, UK), and aliquots were stored at -80°C.
Immunoprecipitation
The cytosolic lysates (300 μg of protein) prepared in
immunoprecipitation buffer (20 mM Tris, pH 7.5, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerol-
phosphate, 1 mM Na3VO4,1μg/ml leupeptin, 1 mM
PMSF) were incubated with a goat anti-MLK3 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) with gentle
rocking overnight at 4°C. PureProteome™protein A mag-
netic beads (Millipore, Billerica, MA) were added (10 μl
of suspension) and rotated for 3 h at 4°C. The beads
were then washed five times with ice-cold immunopreci-
pitation buffer. The pellet was resuspended with 20 μl
3X SDS sample buffer (187.5 mM Tris, pH 6.8, 6% SDS,
30% glycerol, and 0.3% bromophenol blue) either with
or without the reducing agent DTT (final concentration,
150 mM), and boiled for 5 min. The samples were
resolved by sodium dodecyl sulphate-polyacrylamide
(SDS-PAGE) gel electrophoresis and MLK3 or GSK-3b
was detected with antibodies.
Western blotting
Western blot analysis was carried out using antibodies
against phosphorylated members of the MAP kinase
family; the specific phosphorylated sites were: IB-a
(Ser32), NF-B p65 (Ser276, Ser468 and Ser536), c-Jun
(Ser63), MKK4 (Ser257/Thr261), MKK7 (Ser271/
Thr275), and MLK3 (Thr277/Ser281); and an acetylated
site of NF-B p65 (Lys310). Antibodies active against all
forms of each mentioned protein, TFIIB or b-actin were
used as internal controls to determine loading efficiency.
Protein samples containing 50 μg of protein were sepa-
rated on 10% SDS-PAGE gels and transferred to immo-
bilon polyvinylidene difluoride membranes (Millipore).
The membranes were incubated in Tris-buffered saline/
Tween (TBST) buffer (0.1 M Tris/HCl, pH 7.4, 0.9%
NaCl, 0.1% Tween 20) supplemented with 5% dry skim
milk for 1 h to block nonspecific binding. After rinsing
with TBST buffer, they were incubated with primary
antibodies. The membranes were washed twice with
TBST buffer followed by incubation with appropriate
streptavidin-horseradish peroxidase-conjugated second-
ary antibodies. The antigen-antibody complexes were
detected by using a chemiluminescence detection system
(ECL, Amersham, Berkshire, England). The intensity of
the band was quantified with a densitometric analysis
(GS-800 Calibrated Densitometer, Bio-Rad), and calcu-
lated as the optical density × area of band.
ELISA-based DNA binding analysis
The DNA-binding activity of NF-B and activated pro-
tein-1 (AP-1) was quantified by ELISA using EZ-
Detect™NF-B p65 and c-jun Transcription Factor Kits
(Pierce), respectively, according to the manufacturer’s
instructions. Briefly, 5 μg of nuclear extract was incu-
bated in 96-well plates coated with immobilized oligo-
nucleotides containing a consensus binding site for
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3’) for 1 h at room temperature. Following three washes,
primary antibodies specific to p65 (for detection of
NF-B) or c-Jun (for detection of AP-1 complexes)
was added and incubated again at room temperature
for 1 hour. Addition of secondary antibodies conju-
gated to horseradish peroxidase was performed prior
to the quantification of NF-B or AP-1 DNA-binding
activity by measuring luminescence (Fluoroskan Ascent
FL Luminometer, ThermoLabsystems, Fremont, CA).
The specificity of DNA-binding activity was verified by
performing competition assays, in which an excess
amount of soluble oligonucleotides (40 pmoles), that
contained either intact or mutant consensus binding
sequences, was coincubated in the above described
assays.
Transient transfection and luciferase assay
Luciferase reporter plasmids (NF-B-Luc and AP-1-Luc,
Clontech Laboratories, Palo Alto, CA) were transfected
into BV-2 cells using Lipofectamine 2000 (Invitrogen)
according to the protocol of the manufacturer. At 24 h
after transfection, cells were treated with LPS in the
absence or presence of TWS119 or SP600125 for
another 6 h. Luciferase activity of cell lysates was deter-
mined luminometrically by the dual-luciferase assay sys-
tem (Promega) as specified by the manufacturer. Each
transfection was performed in duplicate, and all experi-
ments were repeated at least three times. Luciferase
activity was normalized to the protein content of the
extracts. Relative luciferase activity was determined to
reflect transcriptional activity of NF-Ba n dA P - 1 ,
expressed as the fold increase relative to the activity of
untreated controls.
RNA interference
Murine GSK-3b was targeted with a small interfering
RNA (siRNA) duplex supplied by SignalSilence® GSK-3b
siRNA kit (Cell Signaling), according to the protocol of
the manufacturer. SignalSilence® Control siRNA, a non-
targeted negative control duplex, was used as a control.
siRNA duplexes were transfected into BV-2 cells for 48
h followed by treatment with 100 ng/ml LPS for 6 h.
Released TNF-a was measured by ELISA.
TNF-a assay
Primary microglia and BV-2 microglia were stimulated
with LPS in the absence or presence of GSK-3b inhibi-
tors, and supernatants were collected and kept frozen
in aliquots at -80°C until use. Release of TNF-a was
measured with a commercial enzyme-linked immuno-
sorbent assay (ELISA) kit from R&D Systems (Minnea-
polis, MN) according to the manufacturer’s
instructions.
Statistical analysis
All data are expressed as the mean ± SEM. Data were
analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Scheffe’st e s t .Ap value less than 0.05 was
considered statistically significant.
Results
GSK-3b inhibition decreases TNF-a production in LPS-
stimulated microglia
Because TNF-a has been demonstrated to act as a cen-
tral inflammatory mediator, we tested whether GSK-3b
might modulate microglial activation by examining the
effect of GSK-3b inhibitors on LPS-induced TNF-a
release in microglia. Microglia were pretreated with four
structurally distinct selective GSK-3b inhibitors, TDZD-
8, AR-A014418, L803-mts or TWS119, for 30 min prior
to stimulation with 100 ng/ml LPS. TDZD-8, AR-
A014418 and L803-mts are specific GSK-3b inhibitors
that selectively inhibit GSK-3b activity but do not signif-
icantly affect the activities of other protein kinases
determined by in vitro kinase assays. GSK-3b has been
shown to be the specific cellular target of TWS119,
identified by affinity chromatography and by LC/MS,
and is potently inhibited by this inhibitor [31]. As
s h o w ni nF i g u r e1 A ,a l lG S K - 3 b inhibitors, except
TDZD-8, significantly attenuated TNF-a production in
response to LPS treatment. The GSK-3b inhibitors at
the concentrations used in this study did not show cyto-
toxic effects. Among these inhibitors, TWS119 was
shown to be the most potent inhibitor for reduction of
TNF-a. We further confirmed the intracellular activity
of TWS119 in inhibiting GSK-3b by examining phos-
phorylation of glycogen synthase and accumulation of
b-catenin in TWS119-treated BV-2 cells. TWS119 effec-
tively decreased the phosphorylation of glycogen
synthase, and increased b-catenin levels (Figure 1B).
Therefore, we used TWS119 to further determine the
mechanism by which inactivation of GSK-3b downregu-
lates LPS-induced TNF-a expression. Figure 1C shows
that LPS-induced TNF-a release was robustly suppressed
by TWS119 in a concentration-dependent manner. To
investigate whether the reduction in TNF-a protein in
microglia following a decrease in GSK-3b activity is due
to suppression of TNF-a mRNA expression, real-time
RT-PCR analysis was performed to assess the TNF-a
mRNA levels. The results show that TWS119 treatment
significantly reduced LPS-induced TNF-a mRNA expres-
sion in a dose-dependent manner (Figure 1D).
Loss of endogenous GSK-3b decreases TNF-a production
To further assess the role of endogenous GSK-3b in
LPS-induced TNF-a production, we downregulated
GSK-3b expression using an RNA interference
approach. BV-2 cells were transfected with GSK-3b-
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LPS. After an additional 6 h, TNF-a content in the
supernatant was determined. There was no effect on via-
bility of the cultures following incubation with siRNA
for 48 h. Downregulation of GSK-3b (Figure 2A) signifi-
cantly reduced TNF-a release compared with control
siRNA-treated cells (Figure 2B).
IB-a degradation is not regulated by GSK-3b
We next investigated the molecular mechanisms
involved in the GSK-3b inhibition-mediated reduction
of TNF-a secretion seen in LPS-activated microglia.
Clearly, NF-B appears to be essential for maximal
cytokine transcription after LPS stimulation. To deter-
mine whether GSK-3b inhibition influences LPS-
induced NF-B activation, we assessed the effect of
TWS119 at different levels of the NF-B signaling cas-
cade after LPS stimulation. Activation of the IB
kinase (IKK) complex depends on phosphorylation,
and has been demonstrated to be critical for NF-B
activation. After phosphorylation of IB-a by the IKK
complex, IB-a is degraded and releases NF-B, which
Figure 1 GSK-3b inhibitors inhibit LPS-induced TNF-a production in microglia. (A) Cells were preincubated with vehicle or GSK-3b
inhibitors 10 μM TDZD-8 (TDZD), 10 μM AR-A014418 (AR), 10 μM L803-mts (L803), or 5 μM TWS119 (TWS) for 30 min, and subsequently treated
with 100 ng/ml LPS for 6 h. Released TNF-a was measured by ELISA. Data are presented as mean ± SEM for three independent experiments.
The TNF-a content in untreated cultures or cultures treated with inhibitor alone was not detectable. The levels of TNF-a in LPS-treated alone BV-
2 cells and primary microglia were 3.78 ± 0.27 and 3.49 ± 0.22 ng/ml, respectively. (B) TWS119 inhibits activation of GSK-3b. BV-2 cells were
exposed to DMSO or TWS119 (2.5 μM) for 60 min and analyzed by western blot, using the indicated specific antibodies. (C and D) Cells were
pretreated with vehicle or various concentrations of TWS119 for 30 min followed by treatment with 100 ng/ml LPS for 6 h (C) or 2 h (D).
Released TNF-a (C) is expressed as mean ± SEM for three independent experiments. The levels of TNF-a in LPS-treated alone BV-2 cells and
primary microglia were 3.95 ± 0.32 and 3.62 ± 0.3 ng/ml, respectively. Expression of TNF-a mRNA (D) was quantified by real-time RT-PCR as
described in Methods. The relative differences in expression between groups were analyzed on the basis of cycle time values normalized with b-
actin. The relative differences between control and TWS119 pretreated groups were calculated and expressed as % of control. Data are
presented as mean ± SEM for three independent experiments. *p < 0.05; **p < 0.01 compared with control.
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mined the effect of TWS119 on IB-a phosphorylation
and degradation. BV-2 cells were treated with TWS119
for 30 min prior to addition of LPS. As shown in
Figure 3A, LPS- elicited IKK phosphorylation began
as early as 10 min, increased between 20 and 60 min
and slowly attenuated thereafter. IKK activation pro-
files were similar in cells exposed to TWS119.
Furthermore, TWS119-pretreated BV-2 cells showed
Figure 2 siRNA targeting of GSK-3b inhibits TNF-a production
by LPS-stimulated BV-2 cells. (A) Cells were transfected with GSK-
3b-specific (50 and 100 nM) or control siRNA (100 nM) duplexes for
48 h. Endogenous GSK-3b protein was analyzed by western
blotting. (B) Parallel cultures were exposed to 100 ng/ml LPS for 6
h. Released TNF-a was measured by ELISA. Data are presented as
mean ± SEM for three independent experiments. *p < 0.05; **p <
0.01 compared with control siRNA-transfected cultures. The level of
TNF-a in control cultures was 6.08 ± 0.41 ng/ml.
Figure 3 Blockade of GSK-3b decreases NF-B transcriptional
activity. BV-2 cells were preincubated with vehicle or TWS119 (2.5
μM) for 30 min before stimulation with 100 ng/ml LPS for the
various times indicated. Whole cell lysates and nuclear extracts were
prepared. (A) IB-a degradation is not regulated by GSK-3b.
Western analysis was used to determine total and phosphorylated
IKKa/b and IB-a proteins in whole cell extracts. (B) Localization of
p65 to the nucleus was determined by immunoblotting. TFIIB
immunoblotting was performed to monitor loading. (C) ELISA-based
measurement of p65 DNA binding was analyzed as described in
Methods. (D) Cells were transfected with a 3XNF-B-luciferase
reporter construct. 24 h post-transfection, cells were preincubated
with vehicle or TWS119 (2.5 μM) for 30 min before stimulation with
100 ng/ml LPS for 6 h. Luciferase activity is presented as a fold of
control. Data are presented as mean ± SEM for three independent
experiments. *p < 0.05; **p < 0.01 compared with LPS alone.
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LPS-induced IB-a phosphorylation, degradation, and
resynthesis. The resynthesized IB-a was seen to be
phosphorylated again by sustained IKK activation.
This phenomenon has also been reported for LPS-
challenged murine embryonic fibroblasts in which the
sustained IKK activation is mediated by a TNF-a posi-
tive feedback mechanism following TLR4 signaling
[32,33].
Inhibition of GSK-3b reduces LPS-induced transcriptional
activity of NF-B
We next sought to determine the effects of inhibition of
GSK-3b by TWS119 on downstream signaling of IKK
activation and IB-a degradation. Coincident with the
LPS-elevated IKK activity and subsequent degradation of
IB-a in cells is the release of NF-B for accumulation
in the nucleus. Therefore, we addressed nuclear accu-
mulation of p65 in BV-2 cells. Stimulation with LPS
resulted in elevated levels of p65 in the nuclei of both
control and TWS119-treated cells (Figure 3B). The
nuclear levels of p65 in TWS119-pretreated cells were
similar to controls. Additionally, levels of p65 decreased
at a similar rate in the nuclei of both control and
TWS119-pretreated BV-2 cells, suggesting no defects in
either the rate of p65 nuclear entry or the rate of p65
export following GSK-3b inhibition by TWS119.
We further investigated whether TWS119 affects NF-B
p65 DNA binding activity by using an ELISA-based assay
to measure LPS-induced DNA binding. The results show
a marked increase in amount of p65 bound to consensus
site oligonucleotides fixed to the ELISA plate following
LPS stimulation (Figure 3C). Pretreatment with TWS119
had no effect on LPS-induced p65 DNA binding.
To assess whether the suppressive effect of TWS119 on
TNF-a gene transcription is mediated by downregulating
NF-B transactivation, we transduced BV-2 cells with a
reporter gene in which luciferase transcription is driven
by three NF-B consensus sites. LPS treatment alone
prominently elicited transcriptional activity of the NF-B
consensus promoter in the transfected luciferase reporter
gene. This effect was significantly attenuated by concomi-
tant TWS119 treatment (Figure 3D). These findings con-
firm that the inhibitory effect of inactivated GSK-b on
TNF-a gene expression is, at least partially, mediated by
inhibition of NF-B transactivation activity.
GSK-3b inactivation inhibits NF-B acetylation at Lys310
but not phosphorylation
NF-B activation, characterized by phosphorylation of
specific amino acid residues in the p65 subunit, is one
important prerequisite for transactivation of the target
genes [7,34,35]. We included in our analysis the assessment
of phosphorylation of p65. In control BV-2 cells or primary
microglia, LPS stimulation resulted in enhanced phosphor-
ylation of p65 at Ser276, 468 and 536 (Figure 4A, B). Cells
pretreated with GSK-3b inhibitor TWS119 did not show
compromised induction of phosphorylation at any of the
three sites upon treatment with LPS.
In addition, NF-B signaling is also modulated by
post-translational modifications, including reversible
acetylation of the p65 subunit [36]. Full transcriptional
activity of p65 requires acetylation of Lys310 [37]. Using
an antibody specific for acetylated Lys310, we found
that LPS induced increased levels of acetylated p65
(Figure 4C). Treatment with TWS119 diminished levels
of p65 with acetylated Lys310. These results suggest that
inactivation of GSK-3b downregulates NF-B activation,
possibly by inhibiting acetylation of p65 on Lys310.
GSK-3b inhibition blocks LPS-induced TNF-a production
by inhibiting JNK signaling
LPS is known to stimulate TNF-a production in micro-
glia by activating MAP kinase signaling [38]. To investi-
gate whether these kinases are modulated by GSK-3b,
BV-2 cells were pretreated with TWS119 for 30 min fol-
lowed by stimulation with LPS. Activation of three
MAPKs, including p38, ERK and JNK, was analyzed by
western blotting. As shown in Figure 5A, TWS119 sig-
nificantly reduced the amount of activated JNK but not
p38 MAPK and ERK.
As mentioned above, inhibition of GSK-3b by
TWS119 inhibited LPS-induced phosphorylation of JNK.
c-Jun is a component of the transcription factor AP-1
that binds and activates transcription at TRE/AP-1 ele-
ments. The transcriptional activity of c-Jun is regulated
by phosphorylation at Ser63 and Ser73 [39]. The MAP
kinase JNK binds to the amino-terminal region of c-Jun
and phosphorylates c-Jun at Ser63/73 [40]. Therefore,
we monitored phosphorylation of c-Jun in the
same extracts used to study activation of the MAPKs.
Figure 5B shows LPS-induced phosphorylation of c-Jun
on Ser63 which correlates with the kinetics of JNK acti-
vation by LPS. Pretreatment of BV-2 cells with TWS119
a b r o g a t e dL P S - e v o k e dp h o s p h o r y l a t i o no fc - J u n .
Furthermore, it is well documented that NF-B and AP-
1 transcription factors play a major role in LPS-induced
TNF-a production. First, we examined the effect of
TWS119 on LPS-induced AP-1 DNA binding activity.
Preincubation of cells with TWS119 decreased LPS-sti-
mulated AP-1 binding (Figure 5C). Next, the effect of
inhibition of GSK-3b on gene expression mediated by
AP-1 was determined in BV-2 cells transfected with an
AP-1 binding sites-containing reporter plasmid. As illu-
strated in Figure 5D, TWS119 abolished LPS-induced
AP-1-dependent gene expression.
To further confirm whether JNK is a critical down-
stream signaling molecule in GSK-3b mediation of LPS-
Wang et al. Journal of Neuroinflammation 2010, 7:99
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Page 7 of 18Figure 4 GSK-3b inactivation inhibits NF-B acetylation at Lys310 but not phosphorylation. BV-2 cells (A) or primary microglia (B and C)
were pretreated with vehicle or TWS119 (2.5 μM) for 30 min and then stimulated with LPS (100 ng/ml) for the indicated times. Whole cell
lysates were prepared and subjected to western blotting using antibodies specific for phosphorylated (Ser276, 468 and 536), acetylated (Lys310)
or total forms of p65. The immunoblots are representative of three independent experiments. Data are presented as mean ± SEM for three
independent experiments. **p < 0.01 compared with respective cultures treated with LPS alone.
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Page 8 of 18induced TNF-a production, BV-2 cells were pretreated
with the JNK inhibitor SP600125 and then stimulated
with LPS. We found that SP600125 treatment attenu-
ated LPS-induced c-Jun phosphorylation, AP-1 DNA
binding activity, and AP-1-dependent reporter gene
expression (Figure 6A-C). Furthermore, LPS-induced
TNF-a production was inhibited by SP600125 in a
dose-dependent manner (Figure 6D).
GSK-3b inactivation inhibits MLK3 signaling
To provide further insight into the regulatory role of
GSK-3b in JNK signaling cascades, we investigated the
effect of this enzyme on upstream kinases of the JNK
pathway. JNK activation is regulated by two upstream
mitogen-activated protein kinase (MAPK) kinases,
MKK4 and MKK7 [41,42]. The results show that LPS
treatment failed to cause MKK7 phosphorylation (data
not shown), whereas a lasting activation of the constitu-
tively present MKK4 was induced (Figure 7A). Pretreat-
ment of cells with TWS119 led to suppression of LPS-
induced MKK4 phosphorylation. Mixed lineage kinase 3
(MLK3) is characterized as a MAPK kinase kinase that
activates the JNK pathway through dual phosphorylation
of MKK4/7 [43,44]. To further determine whether
MLK3 is inhibited by GSK-3b inactivation, the same
samples were then examined for MLK3 phosphorylation
Figure 5 Inhibition of GSK-3b activity blocks LPS-induced JNK signaling. BV-2 cells were pretreated with vehicle or TWS119 (2.5 μM) for 30
min and stimulated with LPS (100 ng/ml) for the indicated times. Whole cell extracts or nuclear proteins were isolated. (A) Western analysis was
used to determine LPS-induced p38, ERK and JNK activation in the absence or presence of TWS119. (B) Phosphorylated and total c-Jun was
detected by western blotting in whole cell extracts. (C) ELISA-based measurement of c-Jun DNA binding was analyzed as described in Methods.
Data are presented as mean ± SEM for three independent experiments. *p < 0.05; **p < 0.01 compared with respective LPS-only-treated cells.
(D) Cells were transfected with a 3XAP-1-luciferase reporter construct. 24 h post-transfection, cells were preincubated with vehicle or various
concentrations of TWS119 for 30 min before stimulation with 100 ng/ml LPS for 6 h. Luciferase activity is presented as a fold of control. Data are
presented as mean ± SEM for three independent experiments. **p < 0.01 compared with LPS alone.
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Page 9 of 18using a phospho-specific antibody that detects the
autophosphorylation status of MLK3 at Thr277 and
Ser281, residues necessary for MLK3 kinase activity that
are located within the kinase domain [45]. Figure 7A
shows that LPS induced a time-dependent increase in
MLK3 autophosphorylation and that TWS119 prevented
this phosphorylation. Similar findings were observed
with LPS-stimulated primary microglia, where decreas-
ing GSK-3b activity inhibited MLK3/JNK signaling
(Figure 7B). We next used the MLK3 inhibitor k252a,
which inhibits MLK3 by competing with ATP [46,47], to
investigate the role of MLK3 in the GSK-3b inactivation-
mediated decrease in TNF-a production. LPS-induced
MLK3 autophosphorylation in BV-2 cells was markedly
abolished by k252a (Figure 8A). In addition, k252a also
blocked the LPS-induced downstream phosphorylation of
MKK4 and JNK, leading to suppression of TNF-a release
(Figure 8A, B).
As mentioned above, MLK3 activity was blocked by a
GSK-3b-selective inhibitor, as indicated by reduced
phosphorylation of MKK4, suggesting that GSK-3b lies
upstream of MLK3. GSK-3b appears to inhibit the
autophosphorylation activity of the MLK3 kinase
domain even though the MLK3 kinase domain is not
phosphorylated by GSK-3b [48]. For this reason, the
interaction of endogenous MLK3 and GSK-3b was
examined by coimmunoprecipitation. Immunoprecipi-
tation of cell lysates with anti-MLK3 antibody resulted
in specific coimmunoprecipitation of GSK-3b with
MLK3 (Figure 9A). This interaction was not markedly
Figure 6 SP600125, a JNK inhibitor, mimics GSK-3b inhibitor action in LPS-treated BV-2 cells. Cells were pretreated with vehicle or
SP600125 (SP, 20 μM) for 30 min followed by treatment with LPS (100 ng/ml) for the indicated times. Whole cell extracts or nuclear proteins
were isolated. Western blotting (A) and ELISA-based measurement of c-Jun DNA binding (B) were analyzed as described in Fig. 5. (C) AP-1
luciferase reporter assays were performed by LPS stimulation in the absence or presence of SP600125 (6 h) of BV-2 cells. (D) Cells were
pretreated with various concentrations of SP600125 for 30 min followed by exposure to 100 ng/ml LPS for 6 h. Released TNF-a was measured
by ELISA. Data are presented as mean ± SEM for three independent experiments. **p < 0.01 compared with respective LPS-only-treated cells in
(B) or compared with LPS alone in (C) and (D). The TNF-a content in untreated cultures was not detectable. The level of TNF-a in cells treated
with LPS alone was 4.22 ± 0.25 ng/ml.
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Page 10 of 18affected by exposure of the cells to LPS. Furthermore,
neither the amount nor the duration of GSK-3b asso-
ciation was affected after stimulation with TWS119.
Dimerization of MLK3 has been shown to be a prere-
quisite for its autophosphorylation and, thereby, activa-
tion [49]. To determine whether MLK3 dimerization is
disrupted by inhibiting GSK-3b activity, we used coim-
munoprecipitation and nonreducing SDS-PAGE to
determine the disulfide-linked MLK3 dimer [49].
When separated by SDS-PAGE under nonreducing
conditions, the disulfide bonds of these protein dimers
are preserved and can be detected as protein complexes
migrating at approximately twice the size of the corre-
sponding monomeric form. As shown in Figure 9B, in the
absence of the reducing agent DTT, both monomeric (of
105 KDa) and dimeric (of approximately 220 kDa) forms
of MLK3 was observed. Exposure of cells to LPS resulted
in an increase in MLK3 dimers, whereas inactivation of
GSK-3b by TWS119 blocked MLK3 dimerization.
The interactions of GSK-3b-mediated NF-B and MLK3/
JNK pathways
As mentioned above, both the LPS-activated NF-B and
the MLK3/JNK signaling cascades are mediated by
GSK-3b. However, in activated microglia the interac-
tions of these two pathways are not well understood.
We therefore examined the relationship between NF-B
and MLK3/JNK in the signaling of GSK-3b following
Figure 7 Decreased GSK-3b activity blocks MLK3 signaling. BV-2 cells (A) or primary microglia (B) were pretreated with vehicle or TWS119
(2.5 μM) for 30 min and then stimulated with LPS (100 ng/ml) for the indicated times (A) or 30 min (B). Western analysis was used to determine
total and phosphorylated c-Jun, JNK, MKK4 and MLK3 proteins in whole cell extracts. Data are presented as mean ± SEM for three independent
experiments. **p < 0.01 compared with respective cultures treated with LPS alone.
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Page 11 of 18treatment of microglia with LPS. As shown in Figure 10,
neither a MLK3 inhibitor, K252a nor a JNK inhibitor,
SP600125 had any effect on LPS-induced IB-a degra-
dation (Figure 10A) or NF-B transcriptional activity
(Figure 10B). In addition, neither BAY 11-7082 and
PDTC, two NF-B inhibitors, significantly altered levels
of JNK or c-Jun phosphorylation (Figure 10C). Treat-
ment with a combination of an MLK3/JNK inhibitor
and an NF-B inhibitor showed an additive inhibitory
effect on TNF-a induction compared with each treat-
ment alone (Figure 10D). These data indicate that
GSK-3b-mediated the NF-B and MLK3/JNK signaling
pathways independently lead to induction of TNF-a in
LPS-stimulated microglia.
Discussion
In the present study, we have demonstrated that treat-
ment of microglia with either selective GSK-3b
Figure 8 The MLK3 inhibitor K252a prevents LPS-induced MLK3/JNK signaling cascades and TNF-a production.B V - 2c e l l sw e r e
pretreated with vehicle or 100 nM (A) or various concentrations (B) of K252a for 30 min followed by treatment with 100 ng/ml LPS for the
indicated times (western blotting) or 6 h (TNF-a). Western analysis was performed as described in Fig. 7. Released TNF-a (B) was measured by
ELISA. Data are presented as mean ± SEM of three independent experiments. **p < 0.01 compared with LPS-stimulated alone cultures. The TNF-
a content in untreated cultures was not detectable. The level of TNF-a in cells treated with LPS alone was 4.26 ± 0.14 ng/ml.
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inhibits TNF-a secretion induced by LPS stimulation.
This investigation of the central mechanism by which
GSK-3b positively regulates the inflammatory response
showed that GSK-3b inactivation suppresses TNF-a
production by inhibiting NF-B p65 transactivation
activity through deacetylation of p65 at Lys310. In addi-
t i o n ,w ea l s of o u n dt h a tprevention of MLK3/JNK
signaling cascades is another essential mechanism
responsible for GSK-3b inhibition-mediated anti-inflam-
matory actions.
GSK-3b has been shown to play a critical role in
inflammatory processes [11,50]. We herein examined the
role of GSK-3b in modulating microglial inflammatory
responses. Using pharmacological approaches, we found
that inhibition of GSK-3b can significantly inhibit LPS-
induced TNF-a production in microglia. Furthermore,
treatment of BV-2 microglia with siRNA targeting GSK-
Figure 9 Association of MLK3 and GSK-3b. BV-2 cells were pretreated with vehicle or TWS119 (2.5 μM) for 30 min prior to LPS treatment for
the indicated times. Cell lysates were immunoprecipitated (IP) with goat anti-MLK3 antibody, and the resulting precipitates were separated by
SDS-PAGE in the presence (A) or absence (B) of the reducing agent DTT. Immunoblotting was performed using rabbit anti-GSK-3b antibody or
rabbit anti-MLK3 antibody. The cell extracts were also blotted for MLK3, GSK-3b and b-actin. The band intensity of MLK3 dimers was quantified
with a densitometric analysis, and calculated as the optical density × area of band.
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Page 13 of 183b can block TNF-a release. In the present study, BV-2
microglial cells appear to be more responsive to GSK-3b
inhibitor treatment than are primary microglial, based on
reduction in TNF-a levels. Whether this difference in
sensitivity is due to differential intracellular activity of
i n h i b i t o ro rd i v e r g e n tr e s p o n s et oG S K - 3 b inhibition in
these two cell types needs further investigation. Our data
are consistent with previous reports showing that GSK-
3b positively regulates expression of pro-inflammatory
genes in LPS-stimulated human monocytic cells and
mouse hippocampal slice cultures [11,13,51]. However,
Vines et al. [10] have shown that overexpression of GSK-
3b in endothelial cells significantly inhibits TNF-a-a n d
IL-1b-induced expression of IL-6, monocyte chemoattrac-
tant protein 1, and vascular cell adhesion molecule 1. A
previous report demonstrated that inhibition of GSK-3b
enhances LPS induction of TNF-a expression in cardio-
myocytes [9]. These findings indicate that the role of
GSK-3b in inflammatory responses may depend on cell
type.
Figure 10 GSK-3b-mediated NF-B and MLK3/JNK are two independent signaling pathways in the induction of TNF-a. (A) BV-2 cells
were pretreated with SP600125 (SP, 10 μM), K252a (50 nM), BAY 11-7082 (BAY, 5 μM) or PDTC (20 μM) for 30 min following exposure to 100 ng/
ml LPS for another 30 min. IB-a degradation was determined by western blotting. (B) NF-B luciferase reporter assays were performed by LPS
stimulation in the absence or presence of 10 μM SP600125, 50 nM K252a or 20 μM PDTC (6 h) of BV-2 cells as described in Fig. 3. Data are
presented as mean + SEM for three independent experiments. **p < 0.01 compared with LPS alone. (C) Cells were treated as described in (A).
Phosphorylated and total JNK and c-Jun were detected by western blotting in whole cell extracts. (D) Cells were preincubated with SP600125
(2.5 μM), K252a (12.5 nM), BAY 11-7082 (0.625 μM), SP600125 plus BAY 11-7082 or K252a plus BAY 11-7082 for 30 min, and then treated with 100
ng/ml LPS for 6 h. Released TNF-a was measured by ELISA. Data are presented as mean ± SEM for three independent experiments. #p,# # p or *p
< 0.01 compared with SP600125, K252a or BAY 11-7082 treated cells, respectively. The TNF-a content in untreated cultures was not detectable.
The level of TNF-a in cells treated with LPS alone was 5.74 ± 0.41 ng/ml.
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Page 14 of 18Huang et al. [12] have shown that inhibition of GSK-3
reduces LPS-induced NO and RANTES production by
triggering anti-inflammatory IL-10 upregulation in
microglia. However, our study demonstrates that block-
ing endogenous IL-10 effects by using an anti-IL-10
antibody has no effect on the effects of GSK-3b inhibi-
tors in reducing TNF-a release (data not shown), sug-
gesting that GSK-3b inactivation-mediated decrease of
TNF-a occurs through a distinct mechanism. NF-Bi s
a pluripotent nuclear transcription factor implicated in
the regulation of multiple cellular processes, including
the inflammatory response. A growing body of evidence
suggests that GSK-3b is critically involved in NF-B sig-
naling transduction and is essential for NF-B activation
[52-54]. Recent evidence suggests that inactivation of
GSK-3b only affects downstream events of NF-Ba c t i -
vation, since upstream events like IB-a phosphoryla-
tion and degradation and nuclear accumulation of NF-
B are barely altered by GSK-3b inhibition [11,55]. This
is again confirmed in our present study in microglia.
However, our data regarding the role of GSK-3b in
LPS-induced cytoplasmic signal transduction pathways
differ significantly from those of some reports and sug-
gest cell type-specific functions and stimulus for GSK-
3b. Using TNF-a-treated primary astrocytes, Sanchez et
al. [6] have shown that GSK-3b downregulates IKK
activity, stabilizes IB-a, and prevents p65 accumulation
in nuclei. Another study showed that genetic deletion of
GSK-3b abrogates activation of a number of cytoplasmic
signaling intermediates and nuclear translocation of p65
[8]. Although the early steps leading to NF-B activation
were unaffected by inactivation of GSK-3b,o u rr e s u l t s
show that GSK-3b inhibition attenuates p65-dependent
transcription, suggesting that GSK-3b positively regu-
lates NF-B in LPS-stimulated microglia through reduc-
tion of transactivation activity of p65.
Once activated, NF-B transcriptional activity is
further regulated by inducible post-translational modifi-
cations, including phosphorylation and acetylation
[37,56-58]. A number of different phosphorylation sites
have been identified on the p65 subunit. This phosphory-
lation is essential for NF-B nuclear transportation, sub-
unit dimerization, DNA binding, and finer regulation of
NF-B transcriptional activity [7,34,35,57]. Therefore,
o n ep o s s i b l em e c h a n i s mb yw h i c hG S K - 3 b may control
LPS-induced NF-B activity may be through direct phos-
phorylation of NF-B. Exposure of microglia to LPS
resulted in serine phosphorylation at 276, 468, and 536
sites in p65. However, inhibition of GSK-3b had no sup-
pressive effect on phosphorylation of all three sites. A
previous report implicated GSK-3b in phosphorylation of
p65 at Ser468 and demonstrated that this regulates basal
levels of p65 transactivation in HeLa cells [7]. Gong et al.
[59] reported that GSK-3b inactivation downregulates
NF-B activity via inhibition of p65 phosphorylation at
Ser468 in TNF-a-treated renal tubular epithelial cells.
Our study found no reduction in Ser468 phosphorylation
in microglia pretreated with GSK-3b inhibitor. Possible
interpretations of our findings are that GSK-3b phos-
phorylates p65 at Ser468 in a cell type-specific manner or
that Ser468 phosphorylation under some conditions is
mediated by a multikinase complex.
The nuclear function of the heterodimeric NF-B
transcription factor is regulated in part through reversi-
ble acetylation of its p65 subunit. Site-specific acetyla-
tion of p65 regulates discrete biological actions of the
NF-B complex [37,60]. Acetylation of lysine 310 has
been shown to be required for full transcriptional activ-
ity of p65. In the present study, stimulation of microglia
with LPS increased acetylation of p65 at lysine 310, and
the addition of a GSK-3b inhibitor decreased levels of
acetylated p65, suggesting that GSK-3b inhibition-
mediated downregulation of NF-B transcriptional activ-
ity might be, at least partially, attributable to decreased
p65 acetylation at lysine 310. In the nucleus, p65 associ-
ates with p300/CBP transcriptional co-activators. The
acetyltransferases p300 and CBP appear to play a major
role in the in vivo acetylation of p65 [37,61]. A prior
study demonstrated that GSK-3b inhibition suppresses
the binding of NF-B p65 to the nuclear co-activator
C B P[ 1 1 ] .T h i si si na g r e e m e n tw i t ho u rw o r ks h o w i n g
that acetylation of p65 at lysine 310 is suppressed by
inactive GSK-3b. The phenomenon that inhibition of
GSK-3b impairs acetylation of proteins also occurs for
the tumor suppressor protein p53 [62]. Our data provide
a molecular understanding of how GSK-3b inhibition
suppresses NF-B-mediated production of TNF-a in
LPS-stimulated microglia.
LPS stimulation of microglia activates all three MAPK
pathways: p38, ERK1/2 and JNK [38,63]. Investigation of
the mechanism by which GSK-3b positively regulates
LPS-induced TNF-a demonstrated that loss of GSK-3b
activity abrogated LPS-induced activation of JNK, lead-
ing to decreased c-Jun phosphorylation and AP-1 activa-
tion. Pharmacologically, we further demonstrated that
SP600125, a JNK inhibitor, exhibited a similar ability to
block AP-1 activation and TNF-a production. Studies
on the role of GSK-3b in JNK activation are controver-
sial. One previous study showed that homozygous dis-
ruption of GSK-3b dramatically sensitizes mouse
embryonic fibroblasts to JNK activation induced by lyso-
phosphatidic acid and sphingosine-1-phosphate [64]. On
the contrary, GSK-3b has also been shown to be a posi-
tive regulator of TNF-induced activation of JNK [8].
Furthermore, inhibition of GSK-3b by lithium has no
effect on LPS-induced JNK activation in human mono-
cytic cells [51]. These differences may reflect the use of
different cell types. The present data is the first to show
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JNK activation in microglia, suggesting that the reduc-
tion of LPS-induced TNF-a by GSK-3b inactivation is
due, at least in part, to inhibition of the downstream sig-
naling molecule JNK.
In the JNK pathway, activating stimuli activate
MAP3K members, such as MLK3 or MEKK1, which in
turn phosphorylate MAP2K members such as MKK4
and MKK7. The activated MAP2Ks then phosphorylate
JNK. It has been reported that GSK-3b physically associ-
ates with and activates MEKK1 under either basal or
UV- or TNF-a-stimulated conditions, thereby stimulat-
ing the JNK pathway [65]. The present data demon-
strates that MLK3 inhibitor markedly inhibites JNK
activation, indicating that, in microglia, the activation of
JNK in response to LPS is mediated via MLK3. MLK3
autophosphorylation (Thr277 and Ser281) has been
shown to correlate tightly with activity [45]. Our results
reveal that attenuation of LPS-induced MLK3 autopho-
sphorylation by decreasing GSK-3b activity prevents a
stress kinase cascade that leads to inactivation of JNK.
To our knowledge, there is no prior report about the
effect of GSK-3b on autophosphorylation of MLK3. This
suggests that GSK-3b inhibition abrogates LPS-induced
activation of JNK due, at least partially, to a lack of acti-
vation of MLK3. Dimerization-induced autophosphory-
lation within the kinase domain has been shown to be
essential for activation of MLK3 [49]. Our findings show
that GSK-3b physically interacts with MLK3 and inacti-
vation of GSK-3b results in decreased MLK3 dimeriza-
tion, indicating that this association induces activation
of MLK3 also through a mechanism independent of
direct protein phosphorylation by GSK-3b [48]. Taken
together, our results provide the novel information that
GSK-3b is a potent upstream activator of MLK3 in the
LPS-induced TNF-a production pathway.
Conclusion
Decreasing GSK-3b activity downregulates the transacti-
vation efficiency of NF-B by inhibiting p65 acetylation,
and blocks the MKK4/JNK pathway by disrupting
MLK3 dimerization-induced autophosphorylation, ulti-
mately leading to attenuation of TNF-a production in
LPS-stimulated microglia. Because of the critical roles of
NF-B and JNK/AP-1 in neuroinflammation induced by
a variety of stimuli, and because GSK-3b inhibition
enables simultaneous regulation of multiple transcrip-
tion factors involved in inflammatory signaling [66], one
could postulate that GSK-3b might provide a potential
target for anti-inflammatory intervention. Downregula-
tion of microglia-mediated inflammation by impairing
GSK-3b to prevent neuronal degeneration requires
further in vivo investigation.
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